Last reviewed · How we verify
NCT06006013
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Phase 2 trial testing Pembrolizumab in Locally Advanced Adrenal Cortex Carcinoma in 21 participants. Currently enrolling.
16 December 2027
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 15 January 2025 |
| Primary completion | 16 December 2027 |
| Estimated completion | 16 December 2028 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Pembrolizumab (pembrolizumab) — full drug profile →
- Biospecimen Collection — full drug profile →
- Cabozantinib S-malate — full drug profile →
- Computed Tomography
- Magnetic Resonance Imaging
Conditions studied
- Locally Advanced Adrenal Cortex Carcinoma — all drugs for Locally Advanced Adrenal Cortex Carcinoma →
- Adrenal Cortical Carcinoma — all drugs for Adrenal Cortical Carcinoma →
- Stage III Adrenal Cortex Carcinoma — all drugs for Stage III Adrenal Cortex Carcinoma →
- Stage IV Adrenal Cortex Carcinoma AJCC v8 — all drugs for Stage IV Adrenal Cortex Carcinoma AJCC v8 →
Sponsor
Emory University
Who can join
18 and older, any sex, with Locally Advanced Adrenal Cortex Carcinoma or Adrenal Cortical Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial tests how well cabozantinib in combination with pembrolizumab works in treating patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), that has spread from where it first started (primary site) to other places in the body (metastatic), or that cannot be removed by surgery (unresectable). Cabozantinib inhibits receptor tyrosine kinases, which are receptors commonly over-expressed by tumor cells. This may result in an inhibition of both tumor growth and blood vessel formation, eventually leading to a decrease in tumor size or extent in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Adding cabozantinib to pembrolizumab may be more effective at treating patients with adrenal cortical cancer than giving these drugs alone.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Efficacy and Safety of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
Ababneh O, Ghazou A, Alawajneh M, Alhaj Mohammad S, et al · · 2024 · cited 12× · PMID 38473262 · DOI 10.3390/cancers16050900 -
Oncological Management of Adrenocortical Carcinoma: An Update and Critical Review.
Rowell NP. · · 2025 · cited 1× · PMID 39964565 · DOI 10.1007/s40487-025-00327-5
Verify or expand the search:
- PubMed search for NCT06006013
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pembrolizumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06006013 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 18 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06006013.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing